

Minireview

Recent Advances in Vaccine Adjuvants

Manmohan Singh^{1,2} and Derek T. O'Hagan¹

Received February 28, 2002; accepted March 5, 2002

New generation vaccines, particularly those based on recombinant proteins and DNA, are likely to be less reactogenic than traditional vaccines but are also less immunogenic. Therefore, there is an urgent need for the development of new and improved vaccine adjuvants. Adjuvants can be broadly separated into two classes based on their principal mechanisms of action: vaccine delivery systems and immunostimulatory adjuvants. Vaccine-delivery systems generally are particulate (e.g., emulsions, microparticles, iscoms, and liposomes) and function mainly to target associated antigens into antigen-presenting cells. In contrast, immunostimulatory adjuvants are derived predominantly from pathogens and often represent pathogen-associated molecular patterns (e.g., lipopolysaccharide, monophosphoryl lipid A, CpG DNA), which activate cells of the innate immune system. Recent progress in innate immunity is beginning to yield insight into the initiation of immune responses and the ways in which immunostimulatory adjuvants may enhance this process. The discovery of more potent adjuvants may allow the development of prophylactic and therapeutic vaccines against cancers and chronic infectious diseases. In addition, new adjuvants may also allow vaccines to be delivered mucosally.

KEY WORDS: vaccine adjuvants; immunostimulators; vaccine delivery systems; microparticles; emulsions.

INTRODUCTION

Traditional vaccines have mainly consisted of live attenuated pathogens, whole inactivated organisms, or inactivated bacterial toxins. Generally, these approaches have been successful for vaccine development as a result of the induction of antibodies, which neutralize viruses or bacterial toxins, inhibit the binding of microorganisms to cells, or promote their uptake by phagocytes. However, to develop vaccines against more challenging and difficult pathogens that often establish chronic infections, e.g., HIV, hepatitis C virus (HCV), tuberculosis, and malaria, the induction of potent and focused cell-mediated immunity (CMI) will be necessary and may require the induction of cytotoxic T lymphocytes (CTL), which kill host cells infected with intracellular organisms. Unfortunately, non-living vaccines generally have proven ineffective at inducing potent CMI responses, particularly of the Th1 type. T helper cells can be classified into Th2 and Th1 subtypes, mainly based on their production of cytokines. Th1 responses are characterized by the production of γ interferon. In addition, although live vaccines can induce CTL, live attenuated vaccines may cause disease in immunosuppressed individuals, and some pathogens are difficult or impossible to grow in culture (e.g., HCV), making the development of inactivated vaccines impossible. In addition, many traditional inactivated vaccines based on whole cells often contain components that can cause side effects and safety problems, e.g.,

lipopolysaccharides (LPS). As a result of these limitations, several new approaches to vaccine development have emerged that may have significant advantages over more traditional approaches. These approaches include 1) recombinant protein subunits; 2) synthetic peptides; 3) protein polysaccharide conjugates; and 4) plasmid DNA. Although these new approaches may offer some advantages, a general problem is that the vaccines alone are often poorly immunogenic. Traditional vaccines often contain many components that can elicit additional T cell help or function as adjuvants, e.g., bacterial DNA or LPS in whole cell vaccines. However, these components have been eliminated from new generation vaccines, which, therefore, need potent adjuvants. In the very recent past, there has been great interest in DNA vaccines because they appear to offer significant potential for the induction of potent CTL responses (1). Nevertheless, the potency of DNA vaccines in humans has so far been disappointing, particularly in relation to their ability to induce antibody responses (2,3). This has prompted investigators to work on adjuvants and delivery systems for DNA vaccines and also to use DNA in a prime/boost setting with alternative modalities, e.g., live viruses (4–6).

Immunological adjuvants were described originally by Ramon (7) as “substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone.” This broad definition encompasses a very wide range of materials (8). However, despite extensive evaluation of a large number of candidates over many years, the only adjuvants currently approved by the US Food and Drug Administration are aluminum-based mineral salts (generically called alum). Alum has a good safety record, but comparative studies show that it is a weak adjuvant for anti-

¹ Immunology and Infectious Diseases, Chiron Corporation, 4560 Horton Street, Emeryville, California 94608.

² To whom correspondence should be addressed. (manmohan_singh@chiron.com)

body induction to recombinant protein vaccines and induces a Th2, rather than a Th1 response (9). In addition, Alum is not effective for the induction of mucosal IgA antibody responses. Moreover, alum adjuvants can induce IgE antibody responses and have been associated with allergic reactions in some subjects (9,10). Although Alum has been used as an adjuvant for many years, its mechanism of action remains poorly defined. It was originally thought to provide a "depot" effect, resulting in the persistence of antigen at the injection site. However, more recent studies involving radiolabeled antigens suggest that this is not the case (11). Recent work has indicated that Alum upregulates costimulatory signals on human monocytes and promotes the release of interleukin (IL)-4 (12). Alum adsorption may also contribute to a reduction in toxicity for some vaccines because of the adsorption of contaminating LPS (13).

A key issue in adjuvant development is toxicity because safety concerns have restricted the development of adjuvants since Alum was first introduced more than 50 years ago (14). Many experimental adjuvants have advanced to clinical trials and some have demonstrated high potency, but most have proven too toxic for routine clinical use. For standard prophylactic immunization in healthy individuals, only adjuvants that induce minimal adverse effects will prove acceptable. Additional practical issues that are important for adjuvant development include biodegradability, stability, the ease of manufacture, cost, and applicability to a wide range of vaccines. Examples of different classes of adjuvants that have been evaluated for vaccines against infectious diseases are shown in Table I.

THE ROLE OF ADJUVANTS IN VACCINE DEVELOPMENT

Adjuvants can be used to improve the immune response to vaccine antigens in several different ways, including 1) increasing the immunogenicity of weak antigens; 2) enhancing the speed and duration of the immune response; 3) modulating antibody avidity, specificity, isotype, or subclass distribution; 4) stimulating CTL; 5) promoting the induction of mucosal immunity; 6) enhancing immune responses in immunologically immature or senescent individuals; 7) decreasing the dose of antigen in the vaccine to reduce costs; or 8) helping to overcome antigen competition in combination vaccines.

The mechanisms of action of most adjuvants still remain only poorly understood because immunization often activates a complex cascade of responses and the primary effect of the adjuvant is often difficult to clearly discern. However, if one accepts the geographical concept of immune reactivity, in which antigens that do not reach the local lymph nodes do not induce responses (15), it becomes easier to propose mechanistic interpretations for some adjuvants, particularly those based on a "delivery" mechanism. If antigens, which do not reach lymph nodes, do not induce responses, then any adjuvant that enhances the delivery of antigen into the cells that traffic to the lymph node may enhance the response. A subset of dendritic cells (DCs) are thought to be the key cells that circulate in peripheral tissues and act as "sentinels," being responsible for the uptake of antigens and their transfer to lymph nodes, where they are then presented to T cells. Circulating immature DCs are efficient for antigen uptake, whereas mature DCs are efficient at antigen presentation to T

Table I. Selective List of Different Classes of Adjuvants That Have Been Evaluated for Enhancing Immune Responses to Vaccines

Mineral salts	Aluminum hydroxide*
Aluminum phosphate*	
Calcium phosphate*	
Immunostimulatory adjuvants	Cytokines e.g., IL-2, IL-12, GM-CSF
Saponins e.g., QS21	
MDP derivatives	
Bacterial DNA (CpG oligos)	
LPS	
MPL and synthetic derivatives	
Lipopeptides	
Lipid particles	Emulsions e.g., Freund's, SAF, MF59*
Liposomes	
Virosomes*	
Iscoms	
Cochleates	
Particulate adjuvants	PLG microparticles
Poloxamer particles	
Virus-like particles	
Mucosal adjuvants	Heat labile enterotoxin (LT)
Cholera toxin (CT)	
Mutant toxins e.g., LTK63 and LTR72	
Microparticles	
Polymerized liposomes	
Chitosan	

Note: With the exception of cochleates and polymerized liposomes, all of these adjuvants have been evaluated in clinical trials. However, only those marked* are currently included as adjuvants in approved vaccine products.

cells. Hence, promoting antigen uptake into DC, trafficking to lymph nodes, and DC maturation are thought to be key components to the generation of potent immune responses. DCs are thought to be the most effective antigen-presenting cells (APCs), although macrophages can also function in this role.

The dominant paradigm in immunology for several decades was that the immune system evolved to discriminate self from nonself (16). This hypothesis resulted in significant progress in understanding the clonal recognition of antigenic epitopes mediated by B and T lymphocytes. However, the self/nonself framework offers little insight into why some nonself antigens are found to be poorly immunogenic. In the last decade, alternative models of immunity have been established that emphasize the selective pressures on the host to induce a pro-inflammatory innate immune response after exposure to pathogen-associated molecular patterns (17,18) and tissue damage (19–21). These responses are not antigen-specific and are mediated by the innate immune system, which is the first line of immune defense and is highly conserved throughout many species. s are perceived as "danger signals" after binding to toll-like receptors (TLRs) on phagocytic APCs and induce the release of pro-inflammatory cytokines, which stimulate and focus the adaptive immune response (22,23). In this new model of immunity, vaccines will elicit a potent immune response only when the nonself antigens mimic key aspects of infectious agents or cause some degree of localized tissue damage.

Traditional vaccines such as bacterial toxoids and attenu-

ated viral vaccines often contain most of the features of real pathogens and, therefore, are sufficiently potent to induce protective immune responses. In contrast, recombinant vaccines are highly purified, lack many of the features of the original pathogen, and do not evoke strong immune responses. Hence, it can be argued that the role of adjuvants for recombinant vaccines is to ensure that the vaccine resembles infection closely enough to initiate a potent immune response (17,22). In addition, the innate immune system directs the balance of humoral and CMI (23), and adjuvants can control the type of acquired immune response induced (24). Adjuvants can be divided into different broad groups based on their principal modes of action, depending on whether or not they have direct immunostimulatory effects on APC or function as antigen delivery systems. However, any classification of adjuvants is difficult and many examples resist easy definitions.

IMMUNOSTIMULATORY ADJUVANTS

Monophosphoryl lipid A (MPL) is derived from LPS of *Salmonella minnesota*, a gram-negative bacteria and, therefore, is classified as a PAMP. Like LPS, MPL is thought to interact with TLR4 on APCs, resulting in the release of pro-inflammatory cytokines. In a number of preclinical studies, MPL has been shown to induce the synthesis and release of IL-2 and interferon (IFN)- γ , which promote the generation of Th1 responses (25,26). has been formulated into emulsions to enhance its potency (27). Clinically, MPL has often been used in complex formulations, including liposomes and emulsions, and has also been used in adjuvant combinations with alum and QS21. For example, MPL showed good tolerability and an adjuvant effect in a limited number of volunteers in combination with alum (28). Overall, MPL has been extensively evaluated in the clinic, with >10,000 subjects immunized (T. Ulrich, personal communication) for cancer (melanoma and breast), infectious disease vaccines (genital herpes, HBV, malaria, and HPV), and for allergies, with an acceptable profile of adverse effects. Recently, a vaccine containing MPL was approved in Canada for use against melanoma. In addition, MPL has been approved in Europe for use in combination with allergy vaccines (29). Structure-function studies of MPL allowed identification of a new generation of synthetic adjuvants based on aminoalkyl glucosamine phosphate compounds (30), the lead candidate of which (RC-529), is currently being evaluated in a clinical trial with a recombinant hepatitis B surface antigen (HbsAg). In addition, several synthetic mimetics of MPL are available from alternative sources, which have yet to be evaluated in human subjects (31). It has also been claimed that MPL may be used as an adjuvant for DNA vaccines (32), although these data have been difficult to reproduce, and for mucosal delivery of vaccines (33).

In the last few years, a whole new class of adjuvant active compounds have been identified following the demonstration that bacterial DNA, but not vertebrate DNA, had direct immunostimulatory effects on immune cells *in vitro* (34,35). The immunostimulatory effect was due to the presence of unmethylated CpG dinucleotides (36), which are under-represented, and methylated in vertebrate DNA. Unmethylated CpG in the context of selective flanking sequences is thought to be recognized by cells of the innate immune system to allow

discrimination of pathogen-derived DNA from self DNA (37). It has recently been shown that cellular responses to CpG DNA are mediated by binding to TLR9 (38). Previously, it was reported that CpG are taken up by non-specific endocytosis and that endosomal maturation is necessary for the cell activation and the release of pro-inflammatory cytokines (39). The Th1 adjuvant effect of CpG appears to be maximized by their conjugation to protein antigens (40) or their formulation with delivery systems (Fig. 1) (41). Importantly, CpGs also appear to have potential for the modulation of existing immune responses, which may be useful in various clinical settings, including allergies (42). Although, CpG have mainly been evaluated in rodent models, recent articles have described sequences that are active in primates, including humans (43). In addition, preliminary studies have shown a potent adjuvant effect when CpG was used in combination with HbsAg in human subjects.

A third group of immunostimulatory adjuvants are the triterpenoid glycosides, or saponins, derived from the bark of a Chilean tree, *Quillaja saponaria*. Saponins appear to function mainly through the induction of cytokines. Saponins have been widely used as adjuvants for many years and have been included in several veterinary vaccines. QS21, which is a highly purified fraction from Quil A, has been shown to be a potent adjuvant for Th1 cytokines (IL-2 and IFN- γ) and antibodies of the IgG2a isotype, which indicates a Th1 response in mice (44). Saponins have been shown to intercalate into cell membranes through interaction with structurally similar cholesterol, forming "holes" or pores (45). It is currently unknown whether the adjuvant effect of saponins is related to pore formation; this may allow antigens to gain access to the endogenous pathway of antigen presentation, promoting a CTL response. A number of clinical trials have been per-




Fig. 1. Antibody responses after two intramuscular immunizations 4 weeks apart in mice with CpG adjuvant adsorbed to cationic PLG microparticles co-administered with HIV-1 env gp120 recombinant protein adsorbed onto anionic PLG microparticles. For comparison, we evaluated PLG with gp120 adsorbed and CpG with gp120. In addition, the responses induced were compared to gp120 in MF59. Geometric mean titer \pm SE represented for each group.

formed, using QS21 as an adjuvant, initially for cancer vaccines (melanoma, breast, and prostate), and subsequently for infectious diseases, including HIV-1, influenza, herpes, malaria, and hepatitis B (46), and more than 3,500 people have been immunized with QS21. Doses of 200 μ g or higher of QS21 have been associated with significant local reactions (46), but lower doses appear to be better tolerated. In a recent clinical trial with HIV-1 env antigen, QS21 was able to allow a significant dose reduction for the antigen and also enhanced proliferative T cell responses but not CTL (47). However, pain on injection was a common problem for many vaccine recipients. Hence, the balance of potency vs. adverse events is key for this adjuvant, and an effective adjuvant dose that is tolerable needs to be established in humans for each vaccine indication. A recent study showed that pain at the injection site could be reduced by reformulation of the adjuvant (48). QS21 has also been purported to perform as an adjuvant for DNA vaccines after both systemic and mucosal administration (49). QS21 has also shown enhanced potency in combination with additional adjuvants, to include , CpG DNA, and alternative Quil fractions.

As an alternative to the use of cytokine inducing adjuvants, cytokines may also be used directly. Most cytokines have the ability to modify and redirect the immune response. The cytokines that have been evaluated most extensively as adjuvants include IL-1, IL-2, IFN- γ , IL-12, and GM-CSF (50). However, all of these molecules exhibit dose-related toxicity. In addition, because they are proteins, they have stability problems, a short *in vivo* half-life, and are relatively expensive. Therefore, it is unlikely that cytokines will prove acceptable for use as adjuvants in vaccines designed to protect against infectious diseases. Nevertheless, considerable progress has been made in the use of cytokines for the immunotherapy of cancer (51).

PARTICULATE ANTIGEN DELIVERY SYSTEMS

The use of particulate adjuvants, or antigen delivery systems, as alternatives to immunostimulatory adjuvants has been evaluated by several groups. Particulate adjuvants (e.g., emulsions, microparticles, iscoms, liposomes, virosomes, and virus-like particles) have comparable dimensions to the pathogens that the immune system evolved to combat. Immunostimulatory adjuvants may also be included in particulate delivery systems to enhance the level of response or to focus the response through a desired pathway, e.g., Th1. In addition, formulating potent immunostimulatory adjuvants into delivery systems may limit adverse events, through restricting the systemic circulation of the adjuvant.

Lipid Particles as Adjuvants

A potent oil-in-water (o/w) adjuvant, the syntex adjuvant formulation (52) was developed using a biodegradable oil (squalane) in the 1980s as a replacement for Freund's adjuvants. Freund's adjuvants are strong adjuvants comprised of a water-in-oil emulsion with or without killed mycobacteria (53). However, syntex adjuvant formulation contained a bacterial cell wall-based synthetic adjuvant, threonyl muramyl dipeptide (MDP), and a non-ionic surfactant, poloxamer L121, and proved too toxic for widespread use in humans (14). Therefore, a squalene o/w emulsion was developed

(MF59) without the presence of additional immunostimulatory adjuvants, which proved to be a potent adjuvant with an acceptable safety profile (54). MF59 enhanced the immunogenicity of influenza vaccine in small animal models (55–57) and was shown to be a more potent adjuvant than alum for hepatitis B vaccine (HBV) in baboons (58). Subsequently, the safety and immunogenicity of MF59 adjuvanted influenza vaccine (FLUADTM) was confirmed in elderly subjects in clinical trials (59,60) and these data allowed the approval of this product for licensure in 1997. A recent study has shown that the potency of MF59 as an adjuvant for influenza vaccines might be particularly advantageous to protect against potential pandemic strains of virus (61). The potency of MF59 for HBV has also been confirmed in a human clinical trial, in which MF59 was shown to be 100-fold more potent than the commercial Alum adjuvanted vaccine (Fig. 2) (62). In addition, MF59 has also been shown to be an effective adjuvant for a protein/polysaccharide conjugate vaccines in infant baboons (63). Experience in the clinic (>18,000 subjects immunized in Chiron controlled clinical trials) with HIV, HSV, CMV, HBV, and influenza has shown that MF59 is safe and well-tolerated in humans (64–67). In addition, MF59 was shown to be safe and well-tolerated in newborn infants in a HIV vaccine trial (68). MF59 may also be used with recombinant proteins as an effective booster vaccine after immunization with live viruses (69) or DNA (70) vaccines. In summary, MF59 is a safe and well-tolerated vaccine adjuvant in humans and is effective for the induction of potent antibody responses.

In many studies, emulsions have also been used as delivery systems for immunostimulatory adjuvants, including MPL and QS21. This approach allows immunostimulatory adjuvants to be targeted for enhanced uptake by APC. An o/w emulsion containing MPL and QS21 induced protection in a




Fig. 2. Two injections of MF59 adjuvant in combination with HBV induced significantly higher antibody responses in humans than the commercially available Alum-adsorbed vaccine (Recombivax).

mouse model of malaria that was comparable or better than the levels of protection induced with the vaccine in Freund's complete adjuvant (71). The adjuvant formulation (SBAS-2) subsequently showed protective efficacy against an experimental challenge in human volunteers exposed to infected mosquitoes, although protection was of short duration (72). In a subsequent trial with HIV-1 env, SBAS-2 induced high titers and proliferative T cell responses but did not induce CTL or primary isolate-neutralizing antibodies (73). In addition, the formulation was associated with a significant number of adverse events, and the reactogenicity profile observed appeared to preclude its use for most if not all prophylactic vaccines. An alternative emulsion-based approach involves the use of the Montanide series of adjuvants, which can be formulated as water in oil, o/w, or water in o/w emulsions (74,75). The water in mineral oil (Drakeol) adjuvant (ISA-51) has been evaluated as an immunotherapeutic vaccine in HIV infected individuals (76). However, because of significant adverse effects, mineral oil adjuvants are unlikely to be considered as acceptable for prophylactic vaccines, although they might be appropriate for some therapeutic vaccines. An alternative approach, comprising water in squalene emulsion (ISA-720), has also been evaluated in a malaria vaccine trial (74). However, although potent, this adjuvant induced severe local reactions in some volunteers and may not prove acceptable for routine clinical use in prophylactic vaccines (77,78).

Liposomes are phospholipid vesicles that have been evaluated both as adjuvants and as delivery systems for antigens and adjuvants (79,80). Liposomes have been commonly used in complex formulations, often including MPL, which makes it difficult to determine the contribution of the liposome to the overall adjuvant effect. Nevertheless, several liposomal vaccines based on viral membrane proteins (viro-somes) without additional immunostimulators have been extensively evaluated in the clinic and are approved as products in Europe for hepatitis A and influenza (81). Immunopotentiating reconstituted influenza virosomes are unilamellar liposomes composed of mainly phosphatidylcholine, with influenza haemagglutinin intercalated into the membrane. The use of viral membrane proteins in the formation of virosomes offers the opportunity to exploit the targeting and fusogenic properties of the native viral membrane proteins, perhaps resulting in effective delivery of entrapped antigens into the cytosol for CTL induction (82). An alternative approach to vaccine delivery that may have some advantages over traditional liposomes has been described using "archaeosomes," which are vesicles prepared from the polar lipids of *Archaeobacteria* (83). In some studies, archaeosomes have been shown to be more potent than liposomes (83,84). Cationic lipid vesicles have also been described recently, which comprise cationic cholesterol derivatives with or without neutral phospholipids (85). The best results were obtained with cationic vesicles to which antigen were bound to the surface, which greatly out-performed neutral liposomes, which did not bind antigen (85). O/w liposomal formulations recently were described in which mineral oil was emulsified in the presence of liposomes, which donated phospholipids as stabilizers (86). However, this is a complex formulation, which would need to show a dramatic improvement over alternative approaches before it can be accepted as a significant advance in the field. Modified liposomal structures termed "cochleates" are also being evaluated as systemic and mucosal adjuvants in small

animal models (87). In addition, the development of polymerized liposomes, which show enhanced stability in the gut, also offers potential for the development of mucosal vaccines (88).

The immunostimulatory fractions from Quillaja saponaria (Quil A) have been incorporated into lipid particles containing cholesterol, phospholipids, and cell membrane antigens, which are called iscoms (89). In a study in macaques, an influenza iscom vaccine was shown to be more immunogenic than a classical subunit vaccine and induced enhanced protective efficacy (90). A similar formulation has been evaluated in human clinical trials and has been shown to induce CTL responses (91). The principal advantage of the preparation of iscoms is to allow a reduction in the dose of the hemolytic Quil A adjuvant and to target the formulation directly to APCs. In addition, within the Iscom structure, the Quil A is bound to cholesterol and is not free to interact with cell membranes. Therefore, the hemolytic activity of the saponins is significantly reduced (89,92). It is well established that Iscoms induce cytokine production in a range of mouse strains and a recent study has indicated that the induction of IL-12 is key to the adjuvant effect of iscoms (93). In previous studies, strong IFN- γ responses were also described (94). In a study in rhesus macaques, iscoms induced potent Th1 responses against HIV-1 env, whereas MF59 induced a Th2 response, although both vaccines offered a significant degree of protection against viral challenge (95). Although not evaluated in this study, iscoms are generally considered to be the most potent adjuvant for the induction of CTL responses with recombinant proteins in pre-clinical models. For example, in a recent study, we demonstrated the induction of potent long lasting CTL responses in rhesus macaques immunized with a recombinant core antigen from hepatitis C virus adsorbed to a novel iscom formulation (96). In addition, potent T cell proliferative responses have been induced in primates with iscom vaccines containing CMV, flu, HIV, HCV, and EBV antigens (89,97). However, the efficacy for CTL induction, and the safety profile of iscoms needs to be further established in human subjects, although initial studies are encouraging (98). Iscoms are also being evaluated as cancer vaccines and initial results are promising. A potential problem with iscom's is that inclusion of antigens into the adjuvant is often difficult, and may require extensive antigen modification (99). Nevertheless, recent work has identified novel ways by which some antigens can be effectively associated with iscoms, without significant formulation difficulties (96). Iscoms can also be used for intranasal delivery of vaccines, including influenza virus (97).

An alternative approach involving lipid vesicles has also been described involving non-ionic surfactant vesicle, or "niosomes," which have induced potent responses in small animal models (100). In addition, it has been suggested that an important component of the adjuvant effect of synthetic lipopeptide antigens is their ability to aggregate into particulate structures (101), although interaction with Toll-like receptors is also important. In addition, we have shown that the potency of lipopeptides can be enhanced by their formulation into particulate delivery systems (102).

Microparticles as Adjuvants

Antigen uptake by APCs is enhanced by the association of antigen with polymeric microparticles or by the use of

polymers or proteins that self-assemble into particles. The biodegradable and biocompatible polyesters, the polylactide-co-glycolides (PLGs), are the primary candidates for the development of microparticles as adjuvants because they have been used in humans for many years as suture material and as controlled-release drug-delivery systems (103,104). The adjuvant effect achieved through the encapsulation of antigens into PLG microparticles was first demonstrated by several groups in the early 1990s (105–108). In contrast to alum, PLG microparticles have been shown to be effective for the induction of CTL responses in rodents (102,109,110). The adjuvant effect of microparticles seems to be largely a consequence of their uptake into APC. Microparticles also appear to have significant potential as an adjuvant for DNA vaccines (111,112). We have recently described a novel approach in which cationic microparticles with adsorbed plasmids were used to dramatically enhance the potency of DNA vaccines (112). Importantly, the cationic microparticles enhanced responses in a range of animal models, including non-human primates (Table II). They efficiently adsorbed DNA and delivered several plasmids simultaneously on the same formulation at a range of different loading levels (113,114). The microparticles appeared to be effective as a consequence of efficient delivery of the adsorbed plasmids into DCs, the most important APC for presentation of antigen to naive T cells (115). In addition, cationic microparticles can be used as delivery systems for adjuvant active molecules, including CpG DNA (41). Similar anionic microparticles can also be used for delivery of adsorbed proteins and are effective for CTL induction in mice (116). In a recent study with HIV-1 vaccines, the potency of microparticles as an adjuvant was significantly enhanced by their formulation into MF59 (117). A particularly attractive feature of microparticles is their ability to control the rate of release of entrapped antigens (118,119). Controlled release of antigen may allow the development of single-dose vaccines, which would result in improved vaccine compliance, particularly in the developing world. However, much work is needed to ensure the stability of antigens entrapped in microparticles. It has been shown on several occasions that controlled-release microparticles work optimally for bacterial toxoid based vaccines when they are combined with traditional Alum adjuvants (119). Recent pronouncements suggest that this approach will be evaluated in the clinic in the near future (120).

Polymers that self-assemble into particulates (poloxamers) (121) or soluble polymers (polyphosphazenes) (122) may

also be used as adjuvants, but the safety and tolerability of these approaches remains to be further evaluated.

Recombinant proteins that naturally self assemble into particles can also be used to enhance delivery of antigens to DCs. The first recombinant protein vaccine that was developed, HBsAg, was expressed in yeast as a particulate protein (123). Recombinant HBsAg is potentially immunogenic and can be used to prime CTL responses *in vivo* (124). HBsAg and other virus-like particles (VLPs) can also be used as adjuvants for co-expressed proteins (125). For example, recombinant Ty VLPs from *Saccharomyces cerevisiae* carrying a string of up to 15 CTL epitopes from *Plasmodium* species have been shown to prime protective CTL responses in mice after a single immunization (126). In addition, Ty VLPs have also been shown to induce CTL activity in macaques against co-expressed SIV p27 (127). Clinical trials of Ty VLPs have shown them to be safe and immunogenic in humans (128).

ALTERNATIVE ROUTES OF IMMUNIZATION

Although most vaccines traditionally have been administered by intramuscular or subcutaneous injection, mucosal administration of vaccines offers a number of important advantages, including easier administration, reduced adverse effects, and the potential for frequent boosting. In addition, local immunization induces mucosal immunity at the sites where many pathogens initially establish infection of hosts. In general, systemic immunization has failed to induce mucosal IgA antibody responses. Oral immunization would be particularly advantageous in isolated communities, where access to health care professionals is difficult. Moreover, mucosal immunization would avoid the potential problem of infection resulting from the re-use of needles. Several orally administered vaccines are commercially available that are based on live-attenuated organisms, including vaccines against polio virus, *Vibrio cholerae*, and *Salmonella typhi*. In addition, a wide range of approaches are currently being evaluated for mucosal delivery of vaccines (129), including many approaches involving non-living adjuvants and delivery systems.

The most attractive route for mucosal immunization is oral because of the ease and acceptability of administration through this route. However, as a result of the presence of acidity in the stomach, an extensive range of digestive enzymes in the intestine and a protective coating of mucus that limits access to the mucosal epithelium, oral immunization has proven extremely difficult with non-living antigens. However, novel delivery systems and adjuvants may be used to significantly enhance the responses following oral immunization.

Mucosal Immunization with Microparticles

In mice, oral immunization with PLG microparticles has been shown to induce potent mucosal and systemic immunity to entrapped antigens (130–133). In addition, mucosal immunization with microparticles induced protection against challenge with *Bordetella pertussis* (134–137), *Chlamydia trachomatis* (138), and *Salmonella typhimurium* (139). In primates, mucosal immunization with inactivated SIV in microparticles induced protective immunity against intravaginal challenge (140). Also in primates, mucosal immunization with microparticles induced protection against aerosol challenge with

Table II. Levels of Enhancement of Antibody Responses Achieved with Cationic PLG/DNA Microparticles in Comparison to Naked DNA (HIV-1 gag) after Two Intramuscular Immunizations 4 weeks Apart in Various Animal Models

Species	DNA dose (μ g)	Geometric mean titer serum IgG		Fold increase over naked DNA
		Naked DNA	PLG/CTAB /DNA	
Mice	1 μ g	22	7664	>300
Guinea pigs	100 μ g	868	12882	>15
Rabbits	250 μ g	644	8778	>12
Rhesus macaques	500 μ g	190	10,220	>200

staphylococcal enterotoxin B (141). Comparative studies have indicated that microparticles are one of the most potent adjuvants available for mucosal delivery of vaccines (142). In recent studies, microparticles have also shown some promise for the mucosal delivery of DNA (143,144). The ability of microparticles to perform as effective adjuvants after mucosal administration is largely a consequence of their uptake into the specialized mucosal-associated lymphoid tissue (145). Although most of this work has described particle uptake after oral delivery, a recent paper described the uptake of microparticles into mice following intranasal delivery (146). The potential of microparticles and other polymeric systems for mucosal delivery of vaccines was recently reviewed (147), as was the use of a broader range of antigen delivery systems (148). Although microparticles have significant potential for mucosal delivery of vaccines, their potency may be improved by their use in combination with additional adjuvants. This is likely to be a pre-requisite for the development of effective oral vaccines, since the challenges should not be underestimated. Accumulated experimental evidence suggests that simple encapsulation of vaccines into microparticles is unlikely to result in the successful development of oral vaccines and improvements in the current technology are clearly needed (149).

Adjuvants for Mucosal Immunization

The most potent mucosal adjuvants currently available are the bacterial toxins from *Vibrio cholerae* and *Escherichia coli*, cholera toxin (CT), and heat-labile enterotoxin (LT), respectively. However, because CT and LT are the causes of cholera and travellers diarrhoea, they are generally considered too toxic for use in humans. Therefore, they have been genetically manipulated to reduce toxicity (150–152). Single amino acid substitutions in the enzymatic A subunit of LT allowed the development of mutant toxins that retained potent adjuvant activity, but showed negligible or dramatically reduced toxicity (153–155). LT mutants have been used by the oral route to induce protective immunity in mice against *H. pylori* challenge (156). In addition, LT mutants have been shown to be potent oral adjuvants for influenza vaccine (157) and model antigens (158).

Nevertheless, because of the significant challenges associated with oral immunization, various alternative routes of immunization have been evaluated with LT mutants, including nasal, intravaginal, and intra-rectal. Of these, intranasal immunization offers the most promise, both because of the potent responses induced by this route and the easy access and simple administration devices that already exist. On many occasions, the ability of LT mutants to induce potent antibody responses after intranasal immunization has been demonstrated (159). In recent studies, LT mutants have shown protection against challenge with *B. pertussis* (160), *S. pneumoniae* (161), and herpes simplex virus (162) after intranasal immunization and the induction of potent CTL responses (163,164). In addition, we recently showed that the potency of LT mutants may be enhanced by their formulation into a novel bioadhesive microsphere delivery system (Fig. 3) (165). In addition, the potency of LT mutants was not affected by the presence of pre-existing immunity to the adjuvant (166). A virosomal influenza vaccine with low-dose LT wild type has been evaluated in human clinical trials and showed




Fig. 3. After two intranasal immunizations 4 weeks apart in mice, enhanced serum antibody responses were obtained with influenza vaccine (HA) and mucosal adjuvant LTK63 in combination with bio-adhesive HYAFF microspheres (HA + LTK63 + HYAFF). For comparison, mice were also immunized with antigen alone (HA), antigen and microspheres (HA + HYAFF) or antigen plus adjuvant (HA + LTK63). Geometric mean titer \pm SE represented for each group.

potent responses while appearing to be safe (167,168). The apparent safety of this approach in humans using wild type LT is strongly supportive of the approach using genetically detoxified LT mutants.

Although the mechanisms of action of CT and LT remain to be fully defined, it appears that there are important contributions to the adjuvant effect from the B subunit binding domain, the presence of an intact A subunit, which interacts with regulatory proteins inside cells, and also the enzymatic activity of the A1 subunit (159). Recently, an enzymatically inactive recombinant CT mutant has been proposed to directly activate APC and T cells (169). In addition, the ability of CT to induce the activation and maturation of human DC has been reported (170).

Recent studies have indicated that potent mucosal adjuvants such as CT may also allow vaccination after topical application to the skin (171) and that this approach may be applicable to humans (172). In addition, epidermal immunization may be achieved using needle-free devices, which use helium gas to deposit powdered vaccine into the epidermis (173). An alternative approach to the development of mucosal adjuvants involves the use of plant lectins (174). Furthermore, oral immunization may also be achieved through the ingestion of transgenic plants expressing antigens and adjuvants (175,176).

ADJUVANTS FOR THERAPEUTIC VACCINES

It seems increasingly likely that novel adjuvants may prove sufficiently potent to allow the development of therapeutic vaccines. Rather than prevent infection, therapeutic vaccines would be designed to eliminate or ameliorate existing diseases, including 1) chronic infectious diseases, e.g.,

those caused by HSV, HIV, HCV, HBV, HPV, or *H. pylori*; 2) tumors, e.g., melanoma, breast, or colon cancer; and 3) allergic or autoimmune disorders, e.g., multiple sclerosis, Type I diabetes, and rheumatoid arthritis. For example, a preliminary clinical study in subjects infected with HSV-2 showed a therapeutic benefit following vaccination with an adjuvanted recombinant vaccine (177).

The level of toxicity acceptable for an adjuvant to be used in a therapeutic situation is likely to be higher than for a prophylactic vaccine designed for use in healthy individuals, particularly if the vaccine is designed to treat cancer, or the life-threatening consequences of an infectious disease. However, the acceptable safety profile for any new vaccine/adjuvant combination needs to be established in the clinic. Many adjuvants, including (178), QS21 (28), and cytokines (179) have been evaluated for the development of cancer vaccines and recent data has been encouraging.

Therapeutic vaccines may also be developed for mucosal administration. For example, an LT mutant has been used to eradicate an established infection with *H. pylori* in mice (180). In addition, preliminary studies offered some encouragement that oral administration of antigens can result in the amelioration of autoimmune diseases, including diabetes (181).

FUTURE DEVELOPMENTS IN VACCINE ADJUVANTS

Several recent issues have served to highlight the urgent need for the development of new and improved vaccines. These problems have included 1) the inability of traditional approaches to develop successful vaccines against "difficult" organisms such as HIV and HCV; 2) the emergence of new diseases, for instance, Ebola, West Nile, and nvCJD; 3) the re-emergence of "old" infections like tuberculosis; 4) the continuing spread of antibiotic-resistant bacteria; and 5) the potential use of microorganisms for bioterrorism. In this review, we have suggested that the adjuvants to be used in these vaccines may have to closely mimic an infection and/or induce localized tissue damage to elicit protective immunity. This may be achieved through the use of particulate delivery systems, which have similar dimensions to pathogens and are able to target antigens to macrophages and DCs. In addition, it may also be necessary to deliver one or more adjuvant active, which will more fully activate the innate response and may result in the desired type of adaptive response. If this hypothesis is correct, it suggests that a delicate balance must be maintained between the desired initiation of immune responses and avoidance of the problems potentially associated with a robust response, e.g., local tissue damage and systemic cytokine release. Many of these new generation vaccines will require the induction of potent CMI, including CTL responses. Accumulated research shows that induction of CTL is difficult with proteins and may require much stronger stimulation of the immune system than is normally required for a humoral response. Therefore, DNA remains an attractive approach for many pathogens but needs to be delivered more effectively to improve its potency in humans. In addition, live virus booster immunizations may also be required for optimal induction of CTL.

Targeted delivery of adjuvants and vaccines to specific cell types or tissues may reduce potential toxic effects, or help to achieve a specific desired response. Targeting may be

achieved at several different levels, to include tissue specific delivery to local lymph nodes, cell specific targeting to APC, or targeting to subcellular compartments e.g., the proteasome to promote Class I presentation and CTL, or the nucleus for DNA vaccines. However, "active" targeting may also be achieved through the use of ligands designed to specifically interact with preferred cell types, including the non-clonal receptors on APC, which evolved to recognize various components of bacteria and viruses, including TLR. An alternative target is the mannose receptor, which has been used to target liposomes to APCs (182). Lectins have already been successfully used to target antigens (183), liposomes (184), and microparticles (185) to the M cells of mucosal-associated lymphoid tissue after mucosal delivery. In addition, lectin targeting has also been used to enhance the extent of uptake of microparticles following oral delivery (186). However, the use of targeting ligands on particulate systems requires the construction of a highly sophisticated delivery system, which will be required to show dramatic improvements over non-targeted systems to justify commercialization. Further developments in the delivery of adjuvants may be achieved through the identification of specific receptors on APC, which might be extra- or intracellular. If intracellular, then a means to promote uptake of the delivery system by the relevant cells may also be required for optimal efficacy. An interesting approach to targeting APCs has been described that involves co-expression of two linked proteins, with a targeting component and an adjuvant signal (187–189). An alternative approach to vaccine targeting for CTL induction has also been described using a fusion protein with a bacterial toxin to deliver the antigen specifically to the Class I processing pathway (190,191).

Future developments in adjuvants are likely to include the development of more site-specific delivery systems for both mucosal and systemic administration. In addition, the identification of specific receptors on APCs is likely to allow targeting of adjuvants for the optimal induction of potent and specific immune responses. However, further developments in novel adjuvants will likely be driven by a better understanding of the mechanism of action of currently available adjuvants and this is an area of research that requires additional work.

ACKNOWLEDGMENTS

We would like to acknowledge the contributions of our colleagues in Chiron Corporation to the ideas contained in this review: particularly Rino Rappuoli and John Donnelly. We would also like to thank all the members of the Vaccine Delivery Group at Chiron. Thanks are also due to Nelle Cronen for her help in the manuscript preparation. We are grateful to Terry Ulrich and Charlotte Read-Kensil for the provision of clinical data on and QS21 adjuvants respectively.

References

1. R. A. Seder and S. Gurunathan. DNA vaccines—designer vaccines for the 21st century. *N. Engl. J. Med.* **341**:277–278 (1999).
2. R. Wang, D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, J. Sedegah, C. de Taisne, J. A. Norman, and S. L. Hoffman. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. *Science* **282**:476–480 (1998).

3. S. Calarota, G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom, and B. Wahren. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. *Lancet* **351**:1320–1325 (1998).
4. J. Schneider, S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. *Nat. Med.* **4**:397–402 (1998).
5. N. J. Sullivan, A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. Development of a preventive vaccine for Ebola virus infection in primates. *Nature* **408**:605–609 (2000).
6. R. R. Amara, F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Science* **292**:69–74 (2001).
7. G. Ramon. Sur la toxine et suranatoxine diphtheriques. *Ann. Inst. Pasteur* **38**:1–7 (1924).
8. F. K. Vogel and M. F. Powell. A compendium of vaccine adjuvants and excipients. In M. F. Powell and M. J. Newman (eds.), *Vaccine Design: The Subunit and Adjuvant Approach*, Plenum Press, New York, 1995 pp. 141–228.
9. R. K. Gupta. Aluminum compounds as vaccine adjuvants. *Adv. Drug Deliv. Rev.* **32**:155–172 (1998).
10. E. H. Relyveld, B. Bizzini, and R. K. Gupta. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. *Vaccine* **16**:1016–1023 (1998).
11. R. K. Gupta, A. C. Chang, P. Griffin, R. Rivera, and G. R. Siber. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing ¹⁴C-labeled tetanus toxoid. *Vaccine* **14**:1412–1416 (1996).
12. M. Ulanova, A. Tarkowski, M. Hahn-Zoric, L. A. Hanson, and P. Moingeon. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. *Infect. Immunol.* **69**:1151–1159 (2001).
13. Y. Shi, H. HogenEsch, F. E. Regnier, and S. L. Hem. Detoxification of endotoxin by aluminum hydroxide adjuvant. *Vaccine* **19**:1747–1752 (2001).
14. R. Edelman. Adjuvants for the future. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.), *New Generation Vaccines* Marcel Dekker, Inc., New York, 1997 pp. 173–192.
15. R. M. Zinknagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. *Immunol. Rev.* **156**:199–209 (1997).
16. P. Bretscher and M. Cohn. A theory of self-nonsel discrimination. *Science* **169**:1042–1049 (1970).
17. C. A. Janeway, Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harbor Symp. on Quant. Biol.* **54 Pt 1 C**:1–13 (1989).
18. R. Medzhitov and C. A. Janeway, Jr. Innate immunity: the virtues of a nonclonal system of recognition. *Cell* **91**:295–298 (1997).
19. P. Matzinger. Tolerance, danger, and the extended family. *Annu. Rev. Immunol.* **12**:991–1045 (1994).
20. P. Matzinger. An innate sense of danger. *Semin. Immunol.* **10**:399–415 (1998).
21. Y. Shi, W. Zheng, K. L. Rock, H. HogenEsch, F. E. Regnier, and S. L. Hem. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. *Proc. Natl. Acad. Sci. USA* **97**:14590–14595 (2000).
22. D. T. Fearon. Seeking wisdom in innate immunity. *Nature* **388**:323–324 (1997).
23. D. T. Fearon and R. M. Locksley. The instructive role of innate immunity in the acquired immune response. *Science* **272**:50–53 (1996).
24. H. C. Yip, A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. Adjuvant-guided type-1 and type-2 immu-
- nity: infectious/noninfectious dichotomy defines the class of response. *J. Immunol.* **162**:3942–3949 (1999).
25. G. L. Gustafson and M. J. Rhodes. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. *Res. Immunol.* **143**:483–488 (1992).
26. J. T. Ulrich and K. R. Myers. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions. *Pharm. Biotechnol.* **6**:495–524 (1995).
27. J. T. Ulrich. MPLr immunostimulant: adjuvant formulations. In D. T. O'Hagan (ed.), *Vaccine Adjuvants: Preparation Methods and Research Protocols*. Humana Press Inc., Totowa, New Jersey, 2000 pp. 273–282.
28. S. Thoelen, P. Van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoui, and A. Meheus. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. *Vaccine* **16**:708–714 (1998).
29. A. W. Wheeler, J. S. Marshall, and J. T. Ulrich. A Th1-inducing adjuvant, , enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. *Int. Arch. Allergy Immunol.* **126**:135–139 (2001).
30. D. A. Johnson, D. S. Keegan, C. G. Sowell, M. T. Livesay, C. L. Johnson, L. M. Taubner, A. Harris, K. R. Myers, J. D. Thompson, G. L. Gustafson, M. J. Rhodes, J. T. Ulrich, J. R. Ward, Y. M. Yorgensen, J. L. Cantrell, V. G. Brookshire, and P. Moingeon. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. *J. Med. Chem.* **42**:4640–4649 (1999).
31. L. D. Hawkins, S. T. Ishizaka, P. McGuinness, H. Zhang, W. Gavin, B. DeCosta, Z. Meng, H. Yang, M. Mullarkey, D. W. Young, D. P. Rossignol, A. Nault, J. Rose, M. Przetak, J. C. Chow, and F. Gusovsky. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. *J. Pharmacol. Exp. Ther.* **300**:655–661 (2002).
32. S. Sasaki, T. Tsuji, K. Hamajima, J. Fukushima, N. Ishii, T. Kaneko, K. Q. Xin, H. Mohri, I. Aoki, T. Okubo, K. Nishioka, and K. Okuda. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. *Infect. Immunol.* **65**:3520–3528 (1997).
33. N. K. Childers, K. L. Miller, G. Tong, J. C. Larena, T. Greenway, J. T. Ulrich, S. M. Michalek, and P. Moingeon. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. *Infect. Immunol.* **68**:5509–5516 (2000).
34. J. P. Messina, G. S. Gilkeson, and D. S. Pisetsky. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. *J. Immunol.* **147**:1759–1764 (1991).
35. T. Tokunaga, H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, and T. Sudo. Antitumor activity of deoxyribonucleic acid fraction from *Mycobacterium bovis* BCG. I. Isolation, physicochemical characterization, and antitumor activity. *Infection and Immunity* **72**:955–962 (1984).
36. A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* **374**:546–549 (1995).
37. A. P. Bird. CpG islands as gene markers in the vertebrate nucleus. *Trends Genet.* **3**:342–347 (1987).
38. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, S. Akira, and P. Moingeon. A Toll-like receptor recognizes bacterial DNA. *Nature* **408**:740–745 (2000).
39. T. Sparwasser, E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. *Eur. J. Immunol.* **28**:2045–2054 (1998).
40. D. M. Klinman, K. M. Barnhart, and J. Conover. CpG motifs as immune adjuvants. *Vaccine* **17**:19–25 (1999).
41. M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D. T. O'Hagan. Cationic microparticles are an effective

- tive delivery system for immune stimulatory CpG DNA. *Pharm. Res.* **18**:1476–1479 (2001).
42. D. Broide, J. Schwarze, H. Tighe, T. Gifford, M. D. Nguyen, S. Malek, J. Van Uden, E. Martin-Orozco, E. W. Gelfand, and E. Raz. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. *J. Immunol.* **161**:7054–7062 (1998).
 43. G. Hartmann, R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, H. L. Davis, and A. M. Krieg. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. *J. Immunol.* **164**:1617–1624 (2000).
 44. C. R. Kensil. Saponins as vaccine adjuvants. *Crit. Rev. Ther. Drug Carrier Syst.* **13**:1–55 (1996).
 45. A. M. Glauber, J. T. Dingle, and J. A. Lucy. Action of saponins on biologic membranes. *Nature* **196**:953–959 (1962).
 46. C. R. Kensil and R. Kammer. QS-21: a water-soluble triterpene glycoside adjuvant. *Exp. Opin. Invest. Drugs* **7**:1475–1482 (1998).
 47. T. G. Evans, M. J. McElrath, T. Matthews, D. Montefiori, K. Weinhold, M. Wolff, M. C. Keefer, E. G. Kallas, L. Corey, G. J. Gorse, R. Belshe, B. S. Graham, P. W. Spearman, D. Schwartz, M. J. Mulligan, P. Goepfert, P. Fast, P. Berman, M. Powell, D. Francis, M. L. Clements-Mann, N. Verani-Ketter, S. Erb, C. M. Smith, R. B. Belshe, L. J. Wagner, D. H. Schwartz, and P. Moingeon. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. *Vaccine* **19**:2080–2091 (2001).
 48. D. C. Waite, E. W. Jacobson, F. A. Ennis, R. Edelman, B. White, R. Kammer, C. Anderson, and C. R. Kensil. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. *Vaccine* **19**:3957–3967 (2001).
 49. S. Sasaki, K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. *J. Virol.* **72**:4931–4939 (1998).
 50. A. W. Heath. Cytokines as immunologic adjuvants. In M. F. Powell and M. J. Newman, (eds.), *Vaccine Design: The Subunit and Adjuvant Approach*, Plenum Press, New York, 1995 pp. 645–658.
 51. M. L. Salgaller and P. A. Lodge. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. *J. Surg. Oncol.* **68**:122–138 (1998).
 52. A. C. Allison and N. E. Byars. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. *J. Immunol. Methods* **95**:157–168 (1986).
 53. E. B. Lindblad. Freund's Adjuvants. In D. O'Hagan (ed.), *Vaccine Adjuvants: Preparation methods and research protocols* Humana Press, Totowa, New Jersey, 2000 pp. 49–64.
 54. G. Ott, G. L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In M. F. Powell and M. J. Newman (eds.), *Vaccine Design: The Subunit and Adjuvant Approach*. Plenum Press, New York, 1995 pp. 277–296.
 55. D. M. Cataldo and G. Van Nest. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. *Vaccine* **15**:1710–1715 (1997).
 56. D. A. Higgins, J. R. Carlson, and G. Van Nest. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. *Vaccine* **14**:478–484 (1996).
 57. D. T. O'Hagan, G. S. Ott, and G. Van Nest. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. *Mol. Med. Today* **3**:69–75 (1997).
 58. P. Traquina, M. Morandi, M. Contorni, and G. Van Nest. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. *J. Infect. Dis.* **174**:1168–1175 (1996).
 59. T. Menegon, V. Baldo, C. Bonello, C. D. Dalla, A. Di Tommaso, and R. Trivello. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. *Eur. J. Epidemiol.* **15**:573–576 (1999).
 60. S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, and A. Podda. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. *Vaccine* **17**:3094–3101 (1999).
 61. J. Nicholson. Trade systems in less-developed countries. *Lancet* **357**:1624–1627 (2001).
 62. T. C. Heineman, M. L. Clements-Mann, G. A. Poland, R. M. Jacobson, A. E. Izu, D. Sakamoto, J. Eiden, G. A. Van Nest, and H. H. Hsu. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. *Vaccine* **17**:2769–2778 (1999).
 63. D. M. Granoff, Y. E. McHugh, H. V. Raff, A. S. Mokatri, and G. A. Van Nest. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. *Infect. Immunol.* **65**:1710–1715 (1997).
 64. R. F. Pass, A. M. Duliege, S. Boppana, R. Sekulovich, S. Percell, W. Britt, and R. L. Burke. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. *J. Infect. Dis.* **180**:970–975 (1999).
 65. S. Nitayaphan, C. Khamboonruang, N. Sirisophana, P. Morgan, J. Chiu, A. M. Duliege, C. Chuenchitra, T. Supapongse, K. Rungruehthanakit, M. deSouza, J. R. Mascola, K. Boggio, S. Ratto-Kim, L. E. Markowitz, D. Bix, V. Suriyanon, J. G. McNeil, A. E. Brown, R. A. Michael. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. *Vaccine* **18**:1448–1455 (2000).
 66. J. O. Kahn, F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. *J. Infect. Dis.* **170**:1288–1291 (1994).
 67. A. G. Langenberg, R. L. Burke, S. F. Adair, R. Sekulovich, M. Tigges, C. L. Dekker, and L. Corey. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. *Ann. Intern. Med.* **122**:889–898 (1995).
 68. C. K. Cunningham, D. W. Wara, M. Kang, T. Fenton, E. Hawkins, J. McNamara, L. Mofenson, A. M. Duliege, D. Francis, E. J. McFarland, and W. Borkowsky. Safety of 2 recombinant human immunodeficiency virus type 1 (hiv-1) envelope vaccines in neonates born to hiv-1-infected women. *Clin. Infect. Dis.* **32**:801–807 (2001).
 69. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. *J. Infect. Dis.* **183**:563–570 (2001).
 70. S. Cherpelis, I. Srivastava, A. Gettie, X. Jin, D. D. Ho, S. W. Barnett, and L. Stamatatos. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. *J. Virol.* **75**:1547–1550 (2001).
 71. I. T. Ling, S. A. Ogun, P. Momin, R. L. Richards, N. Garcon, J. Cohen, W. R. Ballou, and A. A. Holder. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. *Vaccine* **15**:1562–1567 (1997).
 72. J. A. Stoute, M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, and M. Marchand. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. *N. Engl. J. Med.* **336**:86–91 (1997).
 73. S. McCormack, A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry, G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J. Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, and J. Weber. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. *Vaccine* **18**:1166–1177 (2000).

74. G. W. Lawrence, A. Saul, A. J. Giddy, R. Kemp, D. Pye, M. Ulanova, A. Tarkowski, M. Hahn-Zoric, L. A. Hanson, and P. Moingeon. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. *Vaccine* **15**:176–178 (1997).
75. J. Aucouturier, V. Ganne, and A. Laval. Efficacy and safety of new adjuvants. *Ann. N. Y. Acad. Sci.* **916**:600–604 (2000).
76. A. Gringeri, E. Santagostino, M. Muca-Perja, P. M. Mannucci, J. F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R. C. Gallo, and D. Zagury. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. *J. Hum. Virol.* **1**: 293–298 (1998).
77. H. Toledo, A. Baly, O. Castro, S. Resik, J. Laferte, F. Rolo, L. Navea, L. Lobaina, O. Cruz, J. Miguez, T. Serrano, B. Sierra, L. Perez, M. E. Ricardo, M. Dubed, A. L. Lubian, M. Blanco, J. C. Millan, A. Ortega, E. Iglesias, E. Penton, Z. Martin, J. Perez, M. Diaz, and C. A. Duarte. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. *Vaccine* **19**: 4328–4336 (2001).
78. B. Genton, F. Al-Yaman, R. Anders, A. Saul, G. Brown, D. Pye, D. O. Irving, W. R. Briggs, A. Mai, M. Ginny, T. Adiguma, L. Rare, A. Giddy, R. Reber-Liske, D. Stuerchler, and M. P. Alpers. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. *Vaccine* **18**:2504–2511 (2000).
79. C. R. Alving. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. *Biochim. Biophys. Acta* **1113**:307–322 (1992).
80. G. Gregoriadis. Immunologic adjuvants: a role for liposomes. *Immunol. Today* **11**:89–97 (1990).
81. F. Ambrosch, G. Wiedermann, S. Jonas, B. Althaus, B. Finkel, R. Gluck, and C. Herzog. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. *Vaccine* **15**:1209–1213 (1997).
82. D. T. Bungener, A. Huckriede, and J. Wilschut. Virosomes as an antigen delivery system. *J. Liposome Res.* **10**:329–338 (2000).
83. L. Krishnan, C. J. Dicaire, G. B. Patel, and G. D. Sprott. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. *Infect. Immunol.* **68**:54–63 (2000).
84. J. W. Conlan, L. Krishnan, G. E. Willick, G. B. Patel, and G. D. Sprott. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, *Listeria monocytogenes*. *Vaccine* **19**:3509–3517 (2001).
85. B. Guy, N. Pascal, A. Francon, A. Bonnin, S. Gimenez, E. Lafay-Vialon, E. Trannoy, and J. Haensler. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. *Vaccine* **19**:1794–1805 (2001).
86. J. M. Muderhwa, G. R. Matyas, L. E. Spitler, and C. R. Alving. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. *J. Pharm. Sci.* **88**:1332–1339 (1999).
87. S. Gould-Fogerite, M. T. Kheiri, F. Zhang, Z. Wang, A. J. Scolino, E. Feketeova, M. Canki, and R. J. Mannino. Targeting immune response induction with cochleate and liposome-based vaccines. *Adv. Drug Deliv. Rev.* **32**:273–287 (1998).
88. H. Chen, V. Torchilin, and R. Langer. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. *J. Control. Release* **42**:263–272 (1996).
89. I. G. Barr, A. Sjolander, and J. C. Cox. ISCOMs and other saponin based adjuvants. *Adv. Drug Deliv. Rev.* **32**:247–271 (1998).
90. G. F. Rimmelzwaan, M. Baars, R. van Beek, G. van Amerongen, K. Lovgren-Bengtsson, E. C. Claas, and A. D. Osterhaus. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. *Vaccine* **78**(Pt 4):757–765 (1997).
91. F. A. Ennis, J. Cruz, J. Jameson, M. Klein, D. Burt, and J. Thipphawong. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). *Virology* **259**:256–261 (1999).
92. S. Soltysik, J. Y. Wu, J. Recchia, D. A. Wheeler, M. J. Newman, R. T. Coughlin, and C. R. Kensil. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. *Vaccine* **13**:1403–1410 (1995).
93. R. E. Smith, A. M. Donachie, D. Grdic, N. Lycke, and A. M. Mowat. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. *J. Immunol.* **162**:5536–5546 (1999).
94. D. L. Emery, J. S. Rothel, and P. R. Wood. Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes. *Immunol. Cell Biol.* **68** (Pt 2):127–136 (1990).
95. E. J. Verschoor, P. Mooij, H. Oostermeijer, M. van der Kolk, P. ten Haaf, B. Verstrepen, Y. Sun, B. Morein, L. Akerblom, D. H. Fuller, S. W. Barnett, and J. L. Heeney. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. *J. Virol.* **73**: 3292–3300 (1999).
96. N. K. Polakos, D. Drane, J. Cox, P. Ng, M. J. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. *J. Immunol.* **166**:3589–3598 (2001).
97. A. Sjolander, D. Drane, E. Maraskovsky, J. Scheerlinck, A. Suhrbier, J. Tennent, and M. Pearce. Immune responses to ISCOM((R)) formulations in animal and primate models. *Vaccine* **19**:2661–2665 (2001).
98. J. Bates, J. Ackland, A. Coulter, J. Cox, D. Drane, R. Macfarlan, J. Varigos, T.-Y. Wong, and W. Woods. IscomT adjuvant - a promising adjuvant for influenza virus vaccines. In L. E. Brown, A. W. Hampson, and R. G. Webster (eds.), *Options for the Control of Influenza III*, Elsevier Science B.V., Amsterdam, 1996 pp. 661–667.
99. K. Lovgren-Bengtsson and B. Morein. The ISCOM™ Technology. In D. T. O'Hagan (ed.), *Vaccine Adjuvants: Preparation Methods and Research Protocols*, Humana Press, Totowa, New Jersey, 2000 pp. 239–258.
100. J. M. Brewer, L. Tetley, J. Richmond, F. Y. Liew, and J. Alexander. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. *J. Immunol.* **161**:4000–4007 (1998).
101. I. Tsunoda, A. Sette, R. S. Fujinami, C. Oseroff, J. Ruppert, C. Dahlberg, S. Southwood, T. Arrhenius, L. Q. Kuang, R. T. Kubo, R. W. Chesnut, and G. Y. Ishioka. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. *Vaccine* **17**:675–685 (1999).
102. D. F. Nixon, C. Hioe, P. D. Chen, Z. Bian, P. Kuebler, M. L. Li, H. Qiu, X. M. Li, M. Singh, J. Richardson, P. McGee, T. Zamb, W. Koff, C. Y. Wang, and D. O'Hagan. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. *Vaccine* **14**:1523–1530 (1996).
103. H. Okada and H. Toguchi. Biodegradable microspheres in drug delivery. *Crit. Rev. Ther. Drug Carrier Syst.* **12**:1–99 (1995).
104. S. D. Putney and P. A. Burke. Improving protein therapeutics with sustained-release formulations. *Nat. Biotechnol.* **16**:153–157 (1998).
105. J. H. Eldridge, J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. *Infect. Immunol.* **59**:2978–2986 (1991).
106. D. T. O'Hagan, D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, S. S. Davis, and S. J. Challacombe. Biodegradable microparticles as controlled release antigen delivery systems. *Immunology* **73**:239–242 (1991).
107. D. T. O'Hagan, H. Jeffery, M. J. Roberts, J. P. McGee, and S. S. Davis. Controlled release microparticles for vaccine development. *Vaccine* **9**:768–771 (1991).
108. D. T. O'Hagan, H. Jeffery, and S. S. Davis. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. *Vaccine* **11**:965–969 (1993).
109. K. J. Maloy, A. M. Donachie, D. T. O'Hagan, and A. M. Mowat. Induction of mucosal and systemic immune responses by immu-

- nization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. *Immunology* **81**:661–667 (1994).
110. A. Moore, P. McGuirk, S. Adams, W. C. Jones, J. P. McGee, D. T. O'Hagan, and K. H. Mills. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8⁺ cytotoxic T lymphocytes and CD4⁺ Th1 cells. *Vaccine* **13**:1741–1749 (1995).
 111. M. L. Hedley, J. Curley, and R. Urban. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. *Nat. Med.* **4**:365–368 (1998).
 112. M. Singh, M. Briones, G. Ott, and D. O'Hagan. Cationic microparticles: A potent delivery system for DNA vaccines. *Proc. Natl. Acad. Sci. USA*. **97**:811–816 (2000).
 113. M. Briones, M. Singh, M. Ugozzoli, J. Kazzaz, S. Klakamp, G. Ott, and D. O'Hagan. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. *Pharm. Res.* **18**:709–711 (2001).
 114. D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, G. R. Otten, and J. B. Ulmer. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. *J. Virol.* **75**:9037–9043 (2001).
 115. K. S. Denis-Mize, M. Dupuis, M. L. MacKichan, M. Singh, D. O'Hagan, J. B. Ulmer, J. Donnelly, D. MacDonald, and G. S. Ott. Plasmid DNA adsorbed onto PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells. *Gene Ther.* **7**:2105–2112 (2000).
 116. J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D. T. O'Hagan. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. *J. Control. Release* **67**:347–356 (2000).
 117. D. T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, K. Higgins, T. C. VanCott, and G. Ott. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. *Vaccine* **18**:1793–1801 (2000).
 118. D. T. O'Hagan. Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.), *New Generation Vaccines*, Marcel Dekker, Inc., New York, 1997 pp. 215–228.
 119. D. T. O'Hagan, M. Singh, and R. K. Gupta. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. *Adv. Drug Deliv. Rev.* **32**:225–246 (1998).
 120. P. Johansen, F. Estevez, R. Zurbriggen, H. P. Merkle, R. Gluck, G. Corradin, and B. Gander. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. *Vaccine* **19**:1047–1054 (2000).
 121. M. J. Newman, M. Balusubramanian, and C. W. Todd. Development of adjuvant-active nonionic block copolymers. *Adv. Drug Deliv. Rev.* **32**:199–223 (1998).
 122. L. G. Payne, S. A. Jenkins, A. L. Woods, E. M. Grund, W. E. Geribo, J. R. Loeblenz, A. K. Andrianov, and B. E. Roberts. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. *Vaccine* **16**:92–98 (1998).
 123. P. Valenzuela, A. Medina, W. J. Rutter, G. Ammerer, and B. D. Hall. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. *Nature* **298**:347–350 (1982).
 124. R. Schirmbeck, W. Bohm, K. Ando, F. V. Chisari, and J. Reimann. Nucleic-acid vaccination primes hepatitis-b virus surface antigen-specific cytotoxic t-lymphocytes in nonresponder mice. *J. Virol.* **69**:5929–5934 (1995).
 125. S. C. Gilbert. Virus-like particles as vaccine adjuvants. In D. O'Hagan (ed.), *Vaccine Adjuvants: Preparation methods and research protocols*, Humana Press, Totowa, New Jersey, 2000 pp. 197–210.
 126. S. C. Gilbert, M. Plebanski, S. J. Harris, C. E. Allsopp, R. Thomas, G. T. Layton, and A. V. Hill. A protein particle vaccine containing multiple malaria epitopes. *Nat. Biotechnol.* **15**:1280–1284 (1997).
 127. L. S. Klavinskis, L. A. Bergmeier, L. Gao, E. Mitchell, R. G. Ward, G. Layton, R. Brookes, N. J. Meyers, and T. Lehner. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. *J. Immunol.* **157**:2521–2527 (1996).
 128. S. J. Martin, A. Vyakarnam, R. Cheingsong-Popov, D. Callow, K. L. Jones, J. M. Senior, S. E. Adams, A. J. Kingsman, P. Matear, and F. M. Gotch. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. *AIDS* **7**:1315–1323 (1993).
 129. M. M. Levine and G. Dougan. Optimism over vaccines administered via mucosal surfaces. *Lancet* **351**:1375–1376 (1998).
 130. S. J. Challacombe, D. Rahman, H. Jeffery, S. S. Davis, and D. T. O'Hagan. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. *Immunology* **76**:164–168 (1992).
 131. S. J. Challacombe, D. Rahman, and D. T. O'Hagan. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. *Vaccine* **15**:169–175 (1997).
 132. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. *J. Control. Release* **11**:205–214 (1990).
 133. D. T. O'Hagan. Microparticles as oral vaccines. In D. T. O'Hagan (ed.), *Novel Delivery Systems for Oral Vaccines*, CRC Press, Inc., Boca Raton, 1994 pp. 175–205.
 134. E. S. Cahill, D. T. O'Hagan, L. Illum, A. Barnard, K. H. Mills, and K. Redhead. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. *Vaccine* **13**:455–462 (1995).
 135. D. H. Jones, B. W. McBride, C. Thornton, D. T. O'Hagan, A. Robinson, and G. H. Farrar. Orally administered microencapsulated *Bordetella pertussis* fimbriae protect mice from B. pertussis respiratory infection. *Infect. Immunol.* **64**:489–494 (1996).
 136. R. Shahin, M. Leef, J. Eldridge, M. Hudson, and R. Gilley. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. *Infect. Immunol.* **63**:1195–1200 (1995).
 137. M. A. Conway, L. Madrigal-Estebas, S. McClean, D. J. Brayden, and K. H. Mills. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. *Vaccine* **19**:1940–1950 (2001).
 138. J. A. Whittum-Hudson, L. L. An, W. M. Saltzman, R. A. Pendergast, and A. B. MacDonald. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. *Nat. Med.* **2**:1116–1121 (1996).
 139. K. Allaoui-Attarki, S. Pecquet, E. Fattal, S. Trolle, E. Chachaty, P. Couvreur, and A. Andremon. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. *Infect. Immunol.* **65**:853–857 (1997).
 140. P. A. Marx, R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamschikov, D. Chen, and J. H. Eldridge. Protection against vaginal SIV transmission with microencapsulated vaccine. *Science* **260**:1323–1327 (1993).
 141. J. Tseng, J. L. Komisar, R. N. Trout, R. E. Hunt, J. Y. Chen, A. J. Johnson, L. Pitt, and D. L. Ruble. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. *Infect. Immunol.* **63**:2880–2885 (1995).
 142. M. Ugozzoli, D. T. O'Hagan, and G. S. Ott. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. *Immunology* **93**:563–571 (1998).
 143. D. H. Jones, S. Corris, S. McDonald, J. C. Clegg, and G. H. Farrar. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. *Vaccine* **15**:814–817 (1997).
 144. E. Mathiowitz, J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chickering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S.

- Montgomery, M. Bassett, and C. Morrell. Biologically erodable microspheres as potential oral drug delivery systems. *Nature* **386**:410–414 (1997).
145. D. T. O'Hagan. The intestinal uptake of particles and the implications for drug and antigen delivery. *J. Anat.* **189**(Pt 3):477–482 (1996).
 146. J. E. Eyles, I. D. Spiers, E. D. Williamson, and H. O. Alpar. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. *J. Pharm. Pharmacol.* **53**: 601–607 (2001).
 147. D. O'Hagan. Microparticles and polymers for the mucosal delivery of vaccines. *Adv. Drug Deliv. Rev.* **34**:305–320 (1998).
 148. S. M. Michalek, D. T. O'Hagan, S. Gould-Fogerite, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and ISCOMS. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (eds.), *Mucosal Immunology*, Academic Press, San Diego, 1999 pp. 759–778.
 149. D. J. Brayden. Oral vaccination in man using antigens in particles: current status. *Eur. J. Pharm. Sci.* **14**:183–189 (2001).
 150. B. L. Dickinson and J. D. Clements. Dissociation of *Escherichia coli* heat-labile enterotoxin adjuvant activity from ADP-ribosyltransferase activity. *Infect. Immunol.* **63**:1617–1623 (1995).
 151. G. Douce, C. Turcotte, I. Copley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. Mutants of *Escherichia coli* heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. *Proc. Natl. Acad. Sci. USA* **92**:1644–1648 (1995).
 152. G. Douce, M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. Intranasal immunogenicity and adjuvant activity of site-directed mutant derivatives of cholera toxin. *Infect. Immunol.* **65**:2821–2828 (1997).
 153. A. Di Tommaso, G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. *Infect. Immunol.* **64**:974–979 (1996).
 154. V. Giannelli, M. R. Fontana, M. M. Giuliani, D. Guangcai, R. Rappuoli, and M. Pizza. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. *Infect. Immunol.* **65**:331–334 (1997).
 155. M. M. Giuliani, G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. Mucosal adjuvant activity and immunogenicity of LTR72, a novel mutant of *Escherichia coli* heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. *J. Exp. Med.* **187**:1123–1132 (1998).
 156. M. Marchetti, M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dougan, R. Rappuoli, and P. Ghiara. Protection against *Helicobacter pylori* infection in mice by intragastric vaccination with *H. pylori* antigens is achieved using a non-toxic mutant of *E. coli* heat-labile enterotoxin (LT) as adjuvant. *Vaccine* **16**:33–37 (1998).
 157. J. D. Barackman, G. Ott, S. Pine, D. T. O'Hagan, D. Campoccia, P. Doherty, M. Radice, P. Brun, G. Abatangelo, and D. F. Williams. Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization. *Clin. Diagn. Lab. Immunol.* **8**: 652–657 (2001).
 158. G. Douce, V. Giannelli, M. Pizza, D. Lewis, P. Everest, R. Rappuoli, and G. Dougan. Genetically detoxified mutants of heat-labile toxin from *Escherichia coli* are able to act as oral adjuvants. *Infect. Immunol.* **67**:4400–4406 (1999).
 159. R. Rappuoli, M. Pizza, G. Douce, and G. Dougan. Structure and mucosal adjuvant activity of cholera and *Escherichia coli* heat-labile enterotoxins. *Immunol. Today* **20**:493–500 (1999).
 160. E. J. Ryan, E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. Mutants of *Escherichia coli* heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. *Infect. Immunol.* **67**:6270–6280 (1999).
 161. H. Jakobsen, D. Schulz, M. Pizza, R. Rappuoli, and I. Jonsdottir. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of *Escherichia coli* heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. *Infect. Immunol.* **67**:5892–5897 (1999).
 162. D. O'Hagan, C. Goldbeck, M. Ugozzoli, G. Ott, R. L. Burke, P. L. Heritage, M. A. Brook, B. J. Underdown, and M. R. McDermott. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. *Vaccine* **17**:2229–2236 (1999).
 163. C. P. Simmons, P. Mastroeni, R. Fowler, M. Ghaem-maghani, N. Lycke, M. Pizza, R. Rappuoli, and G. Dougan. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. *J. Immunol.* **163**:6502–6510 (1999).
 164. J. A. Neidleman, G. Ott, and D. O'Hagan. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In J. M. Walker (ed.), *Methods in Molecular Medicine*, Humana Press, Totowa, New Jersey, 2000 pp. 327–336.
 165. M. Singh, M. Briones, and D. T. O'Hagan. A novel bioadhesive intranasal delivery system for inactivated influenza vaccine. *J. Control. Release* **70**:267–276 (2001).
 166. M. Ugozzoli, G. Santos, J. Donnelly, and D. T. O'Hagan. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of *E. coli* (LT-K63) is not adversely affected by the presence of pre-existing immunity to the adjuvant. *J. Infect. Dis.* **183**(2):351–354 (2001).
 167. U. Gluck, J. O. Gebbers, and R. Gluck. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without *Escherichia coli* heat-labile toxin in adult volunteers. *J. Virol.* **73**: 7780–7786 (1999).
 168. R. Gluck, R. Mischler, P. Durrer, E. Furer, A. B. Lang, C. Herzog, and S. J. Cryz, Jr. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing *Escherichia coli* heat-labile toxin as a mucosal adjuvant. *J. Infect. Dis.* **181**:1129–1132 (2000).
 169. M. Yamamoto, H. Kiyono, S. Yamamoto, E. Batanero, M. N. Kweon, S. Otake, M. Azuma, Y. Takeda, and J. R. McGhee. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvant activity of a nontoxic cholera toxin mutant. *J. Immunol.* **162**:7015–7021 (1999).
 170. M. C. Gagliardi, F. Sallusto, M. Marinaro, A. Langenkamp, A. Lanzavecchia, and M. T. De Magistris. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming. *Eur. J. Immunol.* **30**:2394–2403 (2000).
 171. G. M. Glenn, M. Rao, G. R. Matyas, and C. R. Alving. Skin immunization made possible by cholera toxin. *Nature* **391**:851 (1998).
 172. G. M. Glenn, D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. Transcutaneous immunization: a human vaccine delivery strategy using a patch. *Nat. Med.* **6**:1403–1406 (2000).
 173. D. Chen, R. L. Endres, C. A. Erickson, K. F. Weis, M. W. McGregor, Y. Kawaoka, and L. G. Payne. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. *Nat. Med.* **6**:1187–1190 (2000).
 174. E. C. Lavelle, G. Grant, A. Pusztai, U. Pfuller, and D. T. O'Hagan. The identification of plant lectins with mucosal adjuvant activity. *Immunology* **102**:77–86 (2001).
 175. C. O. Tacket, H. S. Mason, G. Losonsky, J. D. Clements, M. M. Levine, and C. J. Arntzen. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. *Nat. Med.* **4**:607–609 (1998).
 176. L. J. Richter, Y. Thanavala, C. J. Arntzen, and H. S. Mason. Production of hepatitis B surface antigen in transgenic plants for oral immunization. *Nat. Biotechnol.* **18**:1167–1171 (2000).
 177. S. E. Straus, L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, and S. F. Adair. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. *Lancet* **343**:1460–1463 (1994).
 178. B. M. Longenecker, M. Reddish, R. Koganty, and G. D. MacLean. Immune responses of mice and human breast cancer

- patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. *Ann. NY. Acad. Sci.* **690**: 276–291 (1993).
179. B. Agrawal, M. J. Krantz, M. A. Reddish, and B. M. Longenecker. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. *Nat. Med.* **4**:43–49 (1998).
 180. P. Ghiara, M. Rossi, M. Marchetti, A. Di Tommaso, C. Vindigni, F. Ciampolini, A. Covacci, J. L. Telford, M. T. De Magistris, M. Pizza, R. Rappuoli, and G. Del Giudice. Therapeutic intragastric vaccination against *Helicobacter pylori* in mice eradicates an otherwise chronic infection and confers protection against reinfection. *Infect. Immunol.* **65**:4996–5002 (1997).
 181. H. L. Weiner. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. *Immunol. Today* **18**:335–343 (1997).
 182. S. Toda, N. Ishii, E. Okada, K. I. Kusakabe, H. Arai, K. Hamajima, I. Gorai, K. Nishioka, and K. Okuda. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. *Immunology* **92**:111–117 (1997).
 183. P. J. Giannasca, J. A. Boden, and T. P. Monath. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. *Infect. Immunol.* **65**:4288–4298 (1997).
 184. H. Chen, V. Torchilin, and R. Langer. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. *Pharm. Res.* **13**:1378–1383 (1996).
 185. N. Foster, M. A. Clark, M. A. Jepson, and B. H. Hirst. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. *Vaccine* **16**:536–541 (1998).
 186. N. Hussain, P. U. Jani, and A. T. Florence. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. *Pharm. Res.* **14**:613–618 (1997).
 187. L. C. Agren, L. Ekman, B. Lowenadler, and N. Y. Lycke. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. *J. Immunol.* **158**:3936–3946 (1997).
 188. L. C. Agren, L. Ekman, B. Lowenadler, J. G. Nedrud, and N. Y. Lycke. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. *J. Immunol.* **162**: 2432–2440 (1999).
 189. L. Agren, E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. *J. Immunol.* **164**:6276–6286 (2000).
 190. T. J. Goletz, K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. *Proc. Natl. Acad. Sci. USA* **94**:12059–12064 (1997).
 191. H. Cao, D. Agrawal, N. Kushner, N. Touzjian, M. Essex, and Y. Lu. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. *J. Infect. Dis.* **185**: 244–251 (2002).